Print

Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings  
10/23/2012 8:24:54 AM

GHENT, BELGIUM--(Marketwire - October 22, 2012) - Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from KBC Group NV and KBC Private Equity NV.

The above shareholder informed that they have dropped below the 3% threshold.

Full versions of all transparency notifications are available on the website of Ablynx, section Investors.

About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

pdf version of the press release: http://hugin.info/137912/R/1651176/532589.pdf


For more information, please contact:

Ablynx:

Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:

Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com


//-->